Home/Pipeline/MN-246

MN-246

Not specified

Not DisclosedLicensed Asset

Key Facts

Indication
Not specified
Phase
Not Disclosed
Status
Licensed Asset
Company

About MediciNova

MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.

View full company profile

Other Not specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGEN2373 (CD137 Agonist)AgenusNot specified